AgingResearch.NewsJoin free

Diabetes staging system

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab
  • Human trial1

Outcomes

2

Medication adherence

upin humans1

1 study

  1. Diabetes staging system improves medication adherence in humans (MPR ≥80% in 13/13 patients).

    “Medication possession ratio was ≥80% in all 13 patients indicating medication adherence.”

    Human trialin Veterans with type 2 diabetes and CVD/CKD6 monthsn = 13

    Diabetes Staging System (DSS)—A Novel Approach to Improve SGLT2i/GLP-1RA Use and CVD/CKD Outcomes in DM2

    ADA Scientific Sessions 2025 abstract13 Jun 2025

SGLT2 inhibitor or GLP-1 receptor agonist use

upin humans1

1 study

  1. Diabetes staging system increases SGLT2 inhibitor or GLP-1 receptor agonist use in humans (13/14 (93%)).

    “We found 13/14 (93%) patients to still be on at least one of the medications at 6 months.”

    Human trialin Veterans with type 2 diabetes and CVD/CKD6 monthsn = 14

    Diabetes Staging System (DSS)—A Novel Approach to Improve SGLT2i/GLP-1RA Use and CVD/CKD Outcomes in DM2

    ADA Scientific Sessions 2025 abstract13 Jun 2025

Latest

Related